$PFE

Buckley Mortimer J purchased $960K of PFE

Buckley Mortimer J purchased 37,632 shares of PFIZER INC (PFE) at $25.52 ($0.96M total) on 2026-08-05.

Original reporting
SEC EDGAR · Buckley Mortimer J
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PFE
Neutral
medium confidence
Mentioned
$PFE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFENeutralLow
01

Why it matters

A director open-market purchase is incremental sentiment information, not a new fundamental driver.

02

Market read

Traders may note the insider buy, but there is no accompanying guidance, legal, regulatory, or operational update.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it still does not reveal intent, timing constraints, or whether the purchase is meaningful versus prior activity.

Relevance 6/10Novelty 4/10Timing: filed 2026-08-05, after-hours/late session disclosure

Background

The article is a SEC Form 4 insider transaction disclosure for Pfizer Inc.

Company-level read

Ticker impact

$PFENeutralMedium confidence
Context

Pfizer director Buckley Mortimer J bought 37,632 shares in an open-market transaction on 2026-08-05 for about $960K.

Expected impact

Likely limited near-term impact; may modestly support sentiment but is usually not trade-driving alone.

Evidence & confidence

Form 4 insider purchases can be read as confidence signals, yet the filing provides no new company-specific operational or financial information.

Market effects

No direct sector read-through; this is company-specific insider activity without broader industry news.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine, tax-related, or part of personal liquidity planning, so the signal may be weak.

Key entities

  • Pfizer Inc

    Subject of the Form 4 insider transaction disclosure.

  • Buckley Mortimer J

    Director who purchased 37,632 shares on 2026-08-05.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PFEMed

Pfizer Inc Stock (PFE) Moved Up by 3.14% on Oct 14: Drivers Behind the Movement

Pfizer Inc (PFE) stock rose 3.14% on October 14, outperforming its sector and peers. The increase followed a collaboration announcement with Enodia Therapeutics, upcoming research presentations, and positive earnings revisions. Analysts note technical buy signals but caution about downgrades, COVID-19 revenue declines, and patent expirations. The company's revenue was $62.58B, with a net profit of $7.77B. Analysts' average price target is $29.03.

$PFEMedAI 8/10

Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026

Pfizer (NYSE: PFE) will present data from over 50 studies at IDWeek 2026, showcasing advancements in infectious disease prevention and treatment. Key highlights include Phase 2 and 3 results for next-generation vaccines, such as a 25-valent pneumococcal vaccine and a Lyme disease vaccine. The company also shares real-world data on the effectiveness of its RSV and pneumococcal vaccines.

$JNJMedAI 8/10

Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff

Johnson & Johnson (JNJ) stock fell 5% despite raising its full-year outlook due to one-time charges, including talc litigation. Q3 2026 revenue grew 5.9%, but reported net earnings dropped 95.9%. Eli Lilly (LLY) and Pfizer (PFE) also saw declines. JNJ's growth came from its Innovative Medicine division, while MedTech lagged. The company secured market authorization for its OTTAVA robotic surgical system and priority review for RYBREVANT FASPRO.